The impact of cyclosporine dose and level on the development and progression of allograft coronary disease. Sandoz/CVIS Investigators.
Miller
L
L
St. Louis University Health Sciences Center, MO 63110, USA.
Kobashigawa
J
J
Valantine
H
H
Ventura
H
H
Hauptman
P
P
O'Donnell
J
J
Wiedermann
J
J
Yeung
A
A
D000328:Adult; D000368:Aged; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000276:immunology; D012189:Retrospective Studies; D012307:Risk Factors; D017539:Tunica Intima / Q000000981:diagnostic imaging / Q000187:drug effects / Q000276:immunology; D018084:Ultrasonography, Interventional
D007166:Immunosuppressive Agents; D016572:Cyclosporine